Repligen extends Ph II secretin trial in autism

Repligen has extended its Phase II clinical trial of human syntheticsecretin in children with moderate to severe symptoms of autism and gastrointestinal symptoms. All the patients that completed the trial will be offered six doses of secretin over an 18-week period, with the aim of collecting additional, longer-term safety data and extending biological and behavioral observations. Initial Phase II results suggest that secretin causes no serious adverse events and no difference in adverse behavior, compared to placebo. Blood and urine analysis showed no evidence of toxicity associated with three doses of the drug.